Company intelligence / Profile preview

Shanghai Biomabs

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

The denosumab biosimilar (CMAB-807/CMAB-807X) completed Phase 3 trials for osteoporosis in China as of November 2024. Infliximab biosimilar received approval in China in July 2021 for multiple autoimmune indications. Ranibizumab biosimilar (CMAB-818) reached Phase 1 for wet age-related macular degeneration.

Therapeutic areas: ImmunologyRheumatologyOphthalmologyGastroenterologyDermatologyOncologyWomen's Health
Modalities: Monoclonal antibodyAntibodyFab fragment
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Biomabs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Biomabs.

Explore the full profile